Bluebird Bio will sell itself to private equity firms Carlyle and SK Capital for about $30 million, the company said Friday.

Wall Street is still awaiting regulatory approval for the first full-blown private-asset ETFs, but for now opportunistic ...

Private-equity executives entered 2025 with high hopes for a dealmaking recovery that is lifting payouts to fund investors ...

Wall Street is often blamed for reducing corporate managers’ understanding of business to a single, gameable measure of ...

Trump opened the door for private equity to tap 401(k)s, and now private equity bosses want legal protection. Here's what ...

That “waste-to-value” is increasingly getting quiet attention from private equity and infrastructure investors.

In 2025’s go-go leveraged debt markets, everything is up for negotiation, but a trio of investor protections are proving to ...

In 2024, global private equity and venture capital transaction value and volume in biotechnology declined to their lowest ...

As US navigates a shifting landscape of trade policy under new administration, markets grappling with implications of ...

Swedish buyout group EQT named company veteran Per Franzen as its new chief executive and managing partner, replacing ...

With private asset ETFs still awaiting regulatory approval, opportunistic issuers are continuing to crank out products that ...

As private equity continues to shape the Irish M&A landscape, experts predict strong activity in the coming years, fueled by ...